



an Open Access Journal by MDPI

Advanced Research in Endocrine Tumor: Molecular Pathology, Biomarker and Target Therapy 2.0

Guest Editor:

Prof. Dr. Yasuhiro Nakamura

Division of Pathology, Faculty of
Medicine, Tohoku Medical and
Pharmaceutical University,
Miyagi 981-8558, Japan

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editor

Dear Colleagues,

Recent developments in molecular analysis systems have clarified the pathogenesis, novel biomarkers, and prognostic prediction of several types of endocrine tumors, which resulted in significant revisions in the fourth edition of the World Health Organization's classification of endocrine tumors. Therefore, it would be very interesting to specifically focus on these novel findings. I invite you to submit an original research or review article for this Special Issue. It would be an honor to work with you.

Prof. Dr. Yasuhiro Nakamura
Guest Editor



mdpi.com/si/136296

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)